Ipilimumab-Induced Enteritis without Colitis: A New Challenge

Ipilimumab-Induced Enteritis without Colitis: A New Challenge

Introduction: Ipilimumab is an immune checkpoint inhibitor targeting cytotoxic T-lymphocyte associated antigen 4 (CTLA4), approved to treat metastatic melanoma. It was the first therapy shown to prolong survival in a large, randomized clinical trial. However, immune-related adverse events are common...

Full description

Bibliographic Details
Main Authors: Marcus Messmer, Sunita Upreti, Yaman Tarabishy, Nikhilesh Mazumder, Reezwana Chowdhury, Mark Yarchoan, Matthias Holdhoff
Format: Article
Language:English
Published: Karger Publishers 2016-11-01
Series:Case Reports in Oncology
Subjects:
Ipilimumab
CTLA4 inhibitor
Enteritis
Colitis
Immunotherapy
Melanoma
Online Access:http://www.karger.com/Article/FullText/452403

Internet

http://www.karger.com/Article/FullText/452403

Similar Items